Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW61UK)

Drug Name

CRX-526 Drug Info

Synonyms

CRX-526; UNII-8NLO017HHA; 8NLO017HHA; CHEMBL505526; BDBM50275658; 245515-64-4; Hexanoic acid, (1R)-1-(2-(((1S)-1-carboxy-2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)-2-(((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)amino)-4-O-phosphono-beta-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester; N-[(3R)-3-(Hexanoyloxy)myristoyl]-O-[2-[[(3R)-3-(hexanoyloxy)myristoyl]amino]-3-O-[(3R)-3-(hexanoyloxy)myristoyl]-4-O-phosphono-2-deoxy-beta-D-glucopyranosyl]-L-serine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 24849153
CAS Number: CAS 245515-64-4
TTD Drug ID: DMW61UK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Toll-like receptor 4 (TLR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Allergy	4A80-4A85	Preregistration	[2]
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[3]
Resatorvid	DMFMWYC	Sepsis	1G40-1G41	Phase 3	[4]
ERITORAN	DMKQZ0L	Sepsis	1G40-1G41	Phase 3	[5]
G100	DMKHNXA	Non-hodgkin lymphoma	2B33.5	Phase 2	[6]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
NI-0101	DM31FOP	Autoimmune diabetes	5A10	Phase 1	[8]
GSK1795091	DMC6QE4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
CRX-675	DMHDSYF	Hepatitis virus infection	1E50-1E51	Phase 1	[8]
CS-4771	DMVDLT4	Sepsis	1G40-1G41	Discontinued in Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 4 (TLR4)	TTISGCA	TLR4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4.
2	Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
3	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
4	Clinical pipeline report, company report or official report of Takeda (2009).
5	Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
9	Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013